Characterization of the nigroestriatal system in a sample of patients with amyotrophic lateral sclerosis
Authors:
- Claudio Alejandro Jimenez MonsalveCMClaudio Alejandro Jimenez Monsalve
- Luis Henrique Tieppo FornariLFLuis Henrique Tieppo Fornari
- Neivo da Silva JúniorNJNeivo da Silva Júnior
- Douglas Tomio NakataDNDouglas Tomio Nakata
- Eurípedes Gomes de Carvalho NetoENEurípedes Gomes de Carvalho Neto
- Francisco Tellechea RottaFRFrancisco Tellechea Rotta
- Carlos Roberto de Mello RiederCRCarlos Roberto de Mello Rieder
Open Access
- 17 October 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (08) , 806-811
Abstract
Background The coexistence of amyotrophic lateral sclerosis (ALS) with clinical forms of Parkinson disease (PD), although uncommon, is found to a greater degree than one would expect by chance. The pathological mechanisms of ALS and PD are still not fully understood, and the coexistence of these two diseases suggests that they could share mechanisms in common. Objective Here we present a sample of patients with clinically definitive or probable ALS who were evaluated with single-photon emission computed tomography SPECT/TRODAT and compared with non-ALS controls. Methods Patients with clinically definite or probable ALS were assessed with the amyotrophic lateral sclerosis functional rating scale (ALSFRS) to define severity and had their demographic data collected. The TRODAT results of patients with ALS were compared with those of patients with a diagnosis of PD with less than 10 years of duration, and with patients with a diagnosis of others movement disorders not associated with neurodegenerative diseases. Results A total of 75% of patients with ALS had TRODAT results below the levels considered normal; that was also true for 25% of the patients in the control group without neurodegenerative disease, and for 100% of the patients in the PD group. A statistically significant difference was found between patients with ALS and the control group without neurodegenerative disease in the TRODAT values < 0.05. Conclusions Our study fits with the neuropathological and functional evidence that demonstrates the existence of nigrostriatal dysfunction in patients with ALS. Further research to better understand the role of these changes in the pathophysiological process of ALS needs to be performed.Keywords
This publication has 17 references indexed in Scilit:
- ALS and Other Motor Neuron DiseasesContinuum, 2014
- Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s diseaseMolecular Psychiatry, 2013
- Diffusion Tensor Imaging of Basal Ganglia and Thalamus in Amyotrophic Lateral SclerosisJournal of Neuroimaging, 2012
- Pisa syndrome as presenting symptom of amyotrophic lateral sclerosisJournal of Neurology, 2011
- Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonismJournal of the Neurological Sciences, 2011
- Parkinsonism and motor neuron diseases: Twenty‐seven patients with diverse overlap syndromesMovement Disorders, 2010
- Diagnosis and management of motor neurone diseaseBMJ, 2008
- A Positron Emission Tomography Study on the Role of Nigral Lesions in Parkinsonism in Patients With Amyotrophic Lateral SclerosisArchives of Neurology, 2006
- ALS: A Disease of Motor Neurons and Their Nonneuronal NeighborsNeuron, 2006
- Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanningThe Lancet, 1993